Genscript Biotech Corporation (G51) — Capital Reinvestment Ratio
Genscript Biotech Corporation (G51) has a Capital Reinvestment Ratio of 0.26x as of December 2025, meaning it reinvests 0% of its operating cash flow (€325.52 Million) in capital expenditures (€83.84 Million). Check Genscript Biotech Corporation (G51) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Genscript Biotech Corporation Capital Reinvestment Ratio (2016–2025)
This chart tracks Genscript Biotech Corporation's Capital Reinvestment Ratio across 5 annual periods. For the full cash flow conversion analysis, see G51 operating cash flow.
Annual Capital Reinvestment Ratio for Genscript Biotech Corporation (2016–2025)
Year-by-year Capital Reinvestment Ratio for Genscript Biotech Corporation from 2016 to 2025. See Genscript Biotech Corporation free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.26x | €325.52 Million | €83.84 Million | ▼ -86.8% |
| 2024 | 1.96x | €75.65 Million | €147.92 Million | ▲ +749.2% |
| 2018 | 0.23x | €307.66 Million | €70.84 Million | ▼ -83.2% |
| 2017 | 1.37x | €21.37 Million | €29.21 Million | ▲ +406.6% |
| 2016 | 0.27x | €33.27 Million | €8.98 Million | — |